Castle Biosciences, Inc.
CSTL
$21.98
$0.843.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 131.75% | 108.05% | 96.51% | 57.06% | 14.41% |
| Total Depreciation and Amortization | 29.74% | 12.61% | 11.88% | 13.24% | 16.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.01% | 8.51% | 2.63% | 173.84% | 208.69% |
| Change in Net Operating Assets | -113.05% | 22.49% | -140.59% | -772.09% | -94,614.29% |
| Cash from Operations | 1,252.97% | 295.57% | 200.77% | 128.42% | 86.49% |
| Capital Expenditure | -107.96% | -111.38% | -84.22% | -126.83% | -141.85% |
| Sale of Property, Plant, and Equipment | 38.46% | -92.86% | -93.85% | -93.50% | -93.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -747.73% | -2,380.37% | 69.97% | 71.21% | 98.09% |
| Cash from Investing | -209.81% | -389.33% | 57.44% | 64.92% | 90.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 31.69% | 23.57% | 13.14% | -7.52% | -16.39% |
| Issuance of Common Stock | 67.83% | 54.54% | -7.84% | -1.64% | -10.44% |
| Repurchase of Common Stock | -70.67% | -139.36% | -119.57% | -172.05% | -204.15% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 367.15% | 3,204.02% | 1,155.74% | 641.77% | -251.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.56% | 108.70% | 94.19% | 83.59% | 88.34% |